Your browser doesn't support javascript.
Fall 2021 Resurgence and COVID-19 Seroprevalence in Canada: Modelling waning and boosting COVID-19 immunity in Canada, A Canadian Immunization Research Network Study
David W Dick; Lauren M Childs; Zhilan Feng; Jing Li; Gergely Rost; David Buckeridge; Nick Ogden; Jane M Heffernan.
  • David W Dick; York University
  • Lauren M Childs; Virginia Tech
  • Zhilan Feng; Purdue University
  • Jing Li; California State University Northridge
  • Gergely Rost; University of Szeged
  • David Buckeridge; McGill University
  • Nick Ogden; Public Health Agency of Canada
  • Jane M Heffernan; York University
Preprint in English | medRxiv | ID: ppmedrxiv-21262188
ABSTRACT
There is a threat of COVID-19 resurgence in Fall 2021 in Canada. To understand the probability and severity of this threat, quantification of the level of immunity/protection of the population is required. We use an age-structured model including infection, vaccination and waning immunity to estimate the distribution of immunity to COVID-19 in the Canadian population. By late Summer 2021, coinciding with the end of the vaccination program, we estimate that 60 - 80% of the Canadian population will have some immunity to COVID-19. Model results show that this level of immunity is not sufficient to stave off a Fall 2021 resurgence. The timing and severity of a resurgence, however, varies in magnitude given multiple factors relaxation of non-pharmaceutical interventions such as social distancing, the rate of waning immunity, the transmissibility of variants of concern, and the protective characteristics of the vaccines against infection and severe disease. To prevent large-scale resurgence, booster vaccination and/or re-introduction of public health mitigation may be needed.
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint